Women’s Verbal Memory Advantage May Delay Alzheimer’s Diagnosis

Common memory tests may be missing early Alzheimer’s in women

A new study suggests that women may remain classified as cognitively normal for significantly longer than men after Alzheimer’s-related pathology begins accumulating in the brain. The reason, researchers say, is not that the disease is absent, but that women’s stronger baseline verbal memory can mask early decline on the kinds of tests commonly used in clinics.

The study analyzed data from two large long-term studies in the United States and Canada that followed older adults using regular cognitive testing and brain imaging. Some participants eventually developed Alzheimer’s disease. Researchers compared cognitive performance with the accumulation of amyloid pathology, a hallmark associated with the condition, and found that many women continued to pass standard verbal memory testing even after substantial pathology had built up.

On average, women maintained what the study classified as normal test scores for 2.7 years longer than men with the same level of pathology. That gap could have major consequences for diagnosis, access to care, and timing of treatment, particularly as newer therapies depend on identifying the disease earlier in its course.

The issue is not better protection, but better masking

The cognitive test highlighted in the report is familiar in clinical practice. Participants were asked to learn a list of 15 words and recall them immediately, after distraction, and again later. This kind of verbal memory measure is widely used during evaluations for Alzheimer’s disease.

According to the researchers, women’s advantage on such tasks can create what amounts to a diagnostic blind spot. Across the lifespan, women tend to have stronger verbal memory on average than men. That higher baseline may provide greater cognitive reserve when Alzheimer’s pathology begins to affect the brain. In effect, women can lose ground while still appearing normal on the scale used to assess them.

The study’s authors and outside researchers cited in the source frame this as an important sex-related difference in how Alzheimer’s presents. One possibility raised is that women may have stronger connectivity within the brain, allowing function to be maintained longer even as damage accumulates. But whatever the mechanism, the practical implication is the same: standard thresholds on verbal memory tests may not be equally sensitive across sexes.

The clinical cost could be substantial

Delayed diagnosis is not a neutral outcome. If women continue to perform within normal ranges while pathology advances, they may enter treatment pathways later than men, when symptoms are more pronounced and therapeutic options may be less effective. The source text notes that once this cognitive reserve is exhausted, decline can progress quickly.

That matters more now because Alzheimer’s treatment is changing. Newer drugs referenced in the report, including lecanemab and donanemab, are intended for earlier use. Their value depends on identifying patients while disease progression is still at a stage where intervention can meaningfully alter outcomes. A testing system that systematically recognizes women later could therefore create inequity even when clinicians are applying standard tools correctly.

The finding also complicates assumptions about who appears healthy in aging populations. Normal performance on a widely used memory test may not mean the same thing for every patient. It may instead reflect a combination of true function, reserve capacity, and the particular cognitive domain being measured.

Why this changes the diagnostic conversation

The study adds to a growing push for more tailored Alzheimer’s assessment. If verbal memory tests are less sensitive to early disease in women, then clinicians may need sex-informed interpretation, adjusted thresholds, or complementary measures that better capture pathology before reserve masks it.

That does not mean current tests are useless. It means they may be incomplete when used in isolation. Brain imaging and biomarkers have already become more important in research and specialty care, and findings like this strengthen the case for using multiple assessment tools rather than depending too heavily on a single cognitive profile.

There is also a broader lesson for neuroscience and medicine. Population averages can conceal meaningful subgroup differences in disease presentation. When those differences align with standard diagnostic tools, they can influence who gets identified, when they get treated, and how clinical trajectories are interpreted.

What the study does and does not say

The result does not imply that women are less affected by Alzheimer’s pathology. In fact, it suggests the opposite problem: disease may be progressing while typical tests still fail to flag it. Nor does it suggest that every woman will be diagnosed late. Rather, it identifies a pattern across datasets that challenges the assumption that one testing framework performs equally well across sexes.

The study also stops short of prescribing a specific replacement test. Its contribution is diagnostic insight. It shows that verbal memory can act as both a strength and a source of masking, and that the masking effect may extend for nearly three years.

For a disease where timing matters, that is not a marginal detail. It is a reminder that early detection depends not only on having effective treatments or better biomarkers, but also on understanding how disease signs appear differently in different people. In the case of Alzheimer’s, women’s stronger memories may be buying time on paper while costing time in practice.

This article is based on reporting by New Scientist. Read the original article.